The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC

This is an open-label, single-arm, dose-escalation, multicenter phase I/II clinical trial. The primary endpoints of this study were to evaluated the safety, tolerability, pharmacokinetic profile and preliminary efficacy of HE003 in combination with osimertinib in patients with advanced solid tumors who have failed previous standard therapy. The secondary endpoints of this study were to evaluated the efficacy HE003 in combination with osimertinib in patients with advanced solid tumors who have failed previous standard therapy.

Trial Details

NCT ID
NCT06109558
Phase
PHASE1 / PHASE2
Sponsor
Hunan Province Tumor Hospital
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • LMV-12(HE003)
Locations (sample)
  • Changsha, Hunan, China|28.19874,112.97087

Key Eligibility Criteria

  • Eligible subjects selected for this study must meet all of the following criteria:
  • Sign written informed consent before implementing any trial-related procedures;
  • Age ≥18 years old;
  • No limit on the gender;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →